Know Cancer

forgot password

Cilengitide (EMD121974) in Combination With Irradiation in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma: Phase I Study

Phase 1
6 Months
21 Years
Open (Enrolling)
Diffuse Intrinsic Pontine Glioma

Thank you

Trial Information

Cilengitide (EMD121974) in Combination With Irradiation in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma: Phase I Study

Inclusion Criteria:

- Histologically confirmed diffuse intrinsic pontine glioma

- Metastatic disease allowed

- MRI measurable disease according to the WHO criteria and for extension cohort

- Patient is able to undergo functional MRI (diffusion, perfusion, spectro)

- Patient is able to undergo FDG-PET and sestamibi SPECT

- Life expectancy > 8 weeks after the start of study treatment.

- No prior chemotherapy for the present cancer; no treatment for any other cancer
during the last 5 years.

- No prior cerebral radiation therapy

- Age > 6 months and < 21 years

- Lansky Play Scale > 50 or ECOG Performance Status < 2; NB: Children and young adults
with a worse performance status due to glioma-related motor paresis can be included.

- Absolute neutrophils count > 1.5 x 109/l, Platelets > 100 x 109/l

- Total bilirubin < 1,5 x ULN, AST and ALT< 2,5 x ULN

- Serum creatinine ≤ 1,5 X ULN for age. If serum creatinine > 1,5 ULN, creatinine
clearance must be > 70 ml/min/1.73 m² (EDTA radioisotope GFR or 24 hours urines

- Normal coagulation tests : prothrombin rate (prothrombin time = PT), TCA (PTT),

- No current organ toxicity > grade 2 according to the NCICTCAE version 4.0, especially
cardiovascular or renal disease (nephrotic syndrome, glomerulopathy, uncontrolled
high blood pressure despite adequate treatment). In case of known or possible cardiac
disease, a cardiological advice will be required prior to the inclusion in the study

- If anticonvulsants are currently administered, the dosing regimen must be stable
within 1 week prior to the first dose of Cilengitide

- If corticosteroids are administered, the dosing regimen must be stable ≥ 5 days prior
to the first dose of Cilengitide.

- Effective contraception for patients (male and female) of reproductive potential
during their entire participation in the study and during 6 months after the last
administration of Cilengitide.

- Negative pregnancy test (serum beta-HCG) within 1 week prior to start of study
treatment in females of reproductive potential

- Patient covered by government health insurance

- Written informed consent given by patient and/or parents/ guardians prior to the
study participation

Exclusion Criteria:

- Inclusion criteria failure

- History of coagulation disorder associated with bleeding or recurrent thrombotic

- Prior anti-angiogenic therapy

- Any other concomitant anti-cancer treatment not foreseen by this protocol.

- Concomitant inclusion in another therapeutic clinical trial; participation in another
therapeutic clinical trial during the last 30 days.

- Pregnancy or breast feeding woman

- Uncontrolled intercurrent illness or active infection

- Unable for medical follow-up (geographic, social or mental reasons)

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determination of the Maximal Tolerated Dose of Cilengitide

Outcome Description:

A DLT is defined below: Hematological toxicity: grade 4 neutropenia for more than 5 days grade 3 or 4 neutropenia with documented infection grade 3 or 4 thrombopenia for more than 5 days requirement of platelet transfusion support for more than 5 days Non-hematological toxicity: Any grade 3 or 4 non-hematological toxicity of whatever duration with the exception of (i) nausea/vomiting without appropriate treatment, and (ii)isolated, transient fever occurring outside an episode of neutropenia), with the exclusion of toxicities related to any other well-identified cause.

Outcome Time Frame:

After 6 weeks of treatment

Safety Issue:


Principal Investigator


Investigator Role:

Principal Investigator

Investigator Affiliation:

Centre Oscar Lambret


France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:




Start Date:

August 2010

Completion Date:

August 2015

Related Keywords:

  • Diffuse Intrinsic Pontine Glioma
  • Paediatric oncology
  • Cilengitide
  • Glioma
  • Glioma
  • Pontine Glioma